K Maneikis, K Šablauskas, U Ringelevičiūtė… - The Lancet …, 2021 - thelancet.com
Background Haematological malignancies and their treatments are likely to affect SARS- CoV-2 vaccine efficacy. We aimed to evaluate serological response to BNT162b2 vaccine in …
M Mittelman, O Magen, N Barda… - Blood, The Journal …, 2022 - ashpublications.org
Evidence regarding the effectiveness of COVID-19 vaccine in patients with impaired immunity is limited. Initial observations suggest a lower humoral response in these patients …
LM Greenberger, LA Saltzman, JW Senefeld… - Cancer cell, 2021 - cell.com
The mRNA vaccines BNT162b2 and mRNA-1273 have robust safety and efficacy against COVID-19 among immunocompetent individuals (Creech et al., 2021). However, many …
H Ludwig, P Sonneveld, T Facon… - The Lancet …, 2021 - thelancet.com
Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with …
The rapid development of safe and effective vaccines is imperative to attenuate the impact of the COVID-19 pandemic. 1 Patients with multiple myeloma (MM) are at increased risk of …
JC Enssle, J Campe, S Büchel, A Moter, F See… - Cancer Cell, 2022 - cell.com
During the SARS-CoV-2 pandemic, patients with multiple myeloma (MM) are at increased risk of developing severe COVID-19 and succumbing to the disease (Chari et al., 2020) …
Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Neutralizing antibodies (NAbs) against SARS-CoV-2 were …
Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM) patients are immunocompromised and mount suboptimal humoral and cellular responses …